Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

Autor: Sandra Orrù, Emanuele Pascariello, Barbara Pes, Vincenzo Rallo, Raffaele Barbara, Marta Muntoni, Francesca Notari, Gianfranco Fancello, Cristina Mocci, Maria Rosaria Muroni, Paolo Cossu-Rocca, Andrea Angius, Maria Rosaria De Miglio

Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)

Abstract HER2+ breast cancer (BC) is an aggressive subtype genetically and biologically heterogeneous. We evaluate the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in 154 HER2+ BCs pa

Externí odkaz: https://doaj.org/article/36a1b443ba6641c4a88d18e2637049d3

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy

Autor: Grazia Palomba, Mario Budroni, Giuseppe Palmieri, Antonio Cossu, MariaNeve Ombra, Valeria Pusceddu, Francesca Notari, MariaCristina Sini, Francesco Atzori, Bruno Massidda, MariaTeresa Ionta, B. Frau

Publikováno v: Journal of Translational Medicine
Journal of translational medicine (Online) 12 (2014): 1–8. doi:10.1186/s12967-014-0272-4
info:cnr-pdr/source/autori:Palomba G.; Atzori F.; Budroni M.; Ombra M.; Cossu A.; Sini M.; Pusceddu V.; Massidda B.; Frau B.; Notari F.; Ionta M.; Palmieri G./titolo:ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy/doi:10.1186%2Fs12967-014-0272-4/rivista:Journal of translational medicine (Online)/anno:2014/pagina_da:1/pagina_a:8/intervallo_pagine:1–8/volume:12

Background: Polymorphisms in the excision repair cross-complimentary group 1 (ERCC1) gene have been involved in the prognosis of various cancers. In the present study, we evaluated the prognostic role of the two most common ERCC1 polymorphisms in pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f41046eba7abccb3e875e27303c0a25d
https://doi.org/10.1186/s12967-014-0272-4